Boston Partners Takes $19.40 Million Position in Harmony Biosciences Holdings, Inc. $HRMY

Boston Partners purchased a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 605,495 shares of the company’s stock, valued at approximately $19,398,000. Boston Partners owned approximately 1.05% of Harmony Biosciences as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in HRMY. CWM LLC lifted its stake in Harmony Biosciences by 34.8% during the first quarter. CWM LLC now owns 2,704 shares of the company’s stock worth $90,000 after purchasing an additional 698 shares during the last quarter. Cetera Investment Advisers increased its position in Harmony Biosciences by 10.9% during the first quarter. Cetera Investment Advisers now owns 7,656 shares of the company’s stock worth $254,000 after buying an additional 754 shares during the period. GSA Capital Partners LLP purchased a new stake in Harmony Biosciences in the first quarter valued at approximately $688,000. XTX Topco Ltd boosted its holdings in shares of Harmony Biosciences by 259.4% in the first quarter. XTX Topco Ltd now owns 24,499 shares of the company’s stock valued at $813,000 after acquiring an additional 17,683 shares during the period. Finally, Foster & Motley Inc. purchased a new stake in Harmony Biosciences in the 1st quarter valued at $350,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

Harmony Biosciences stock opened at $35.26 on Friday. The stock has a fifty day moving average price of $29.97 and a 200 day moving average price of $33.02. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18. Harmony Biosciences Holdings, Inc. has a 52 week low of $25.52 and a 52 week high of $40.93. The firm has a market capitalization of $2.03 billion, a P/E ratio of 11.09, a PEG ratio of 0.46 and a beta of 0.85.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.05). The company had revenue of $239.46 million for the quarter, compared to analyst estimates of $222.68 million. Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%. Equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on HRMY shares. UBS Group reduced their target price on shares of Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Wall Street Zen cut Harmony Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Oppenheimer reissued an “outperform” rating and issued a $62.00 target price on shares of Harmony Biosciences in a report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of Harmony Biosciences in a report on Monday, November 24th. Finally, Mizuho upped their target price on Harmony Biosciences from $36.00 to $39.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Harmony Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $44.75.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.